Genzyme re-ups and beefs up business with Hospira for fill/finish ops

Genzyme will have Hospira conduct the final steps of manufacturing for a growing list of drugs under a new supply agreement. Hospira will provide fill/finish services for Cerezyme, Fabrazyme, Thyrogen and Myozyme, as it has been according to a previous agreement, as well as Lumizyme, Thymoglobulin, Campath and products in development. Article

Suggested Articles

Mount Fuji Japan with cherry blossoms
Vaccines

Takeda signs on to introduce Novavax's COVID-19 shot in Japan

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

by Angus Liu
Pfizer headquarters logo sign
Manufacturing

Pfizer signs up to manufacture Gilead's COVID-fighter remdesivir

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

by Eric Sagonowsky
CG image of AstraZeneca's HQ
Manufacturing

Japan will buy 120 million shots from AZ starting early in 2021

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

by Fraiser Kansteiner